Independent · Source-linked · Human-verified

Is that peptide legal right now?

Peptlas tracks where 26 peptides stand with the FDA and five other regulators - each answer dated, linked to its primary source, and checked every six hours. Headlines and the law often disagree; we show you the law. We sell nothing.

Are peptides legal? The short answer Browse all 26 by status How we track it

The July vote, corrected

The FDA committee voted on July 23-24, 2026. It recommended six of seven peptides for the 503A list and rejected one. It is being widely reported as the FDA legalising them. It did not. The votes are advisory, the FDA has not acted, and not one of the seven is on the list today. That gap between headline and law has its own status here: In limbo

See every vote, and what it actually changed →Next: a second FDA peptide meeting, expected before the end of February 2027 (no date published) →

The atlas

Every compound we track, grouped by U.S. status - most time-sensitive first.

A–Z index
KeyUnder reviewIn limboRestrictedCompounding-legalUnscheduledWhat they mean

We never reduce this to “legal / illegal.” Every badge pairs a color with a word, so status is readable without relying on color.

Under review
Actively before the FDA advisory committee; a decision is pending and the status can move.
In limbo
Moved on paper - nominated, removed from a restricted list, or recommended by an FDA committee - but not added to the 503A list. The headline implies a change; the legal status has not moved.
Restricted
Prescription-only, banned, controlled, or under active FDA enforcement.
Compounding-legal
A licensed pharmacy may compound it on prescription: it is on the FDA 503A bulk-substances list or is an ingredient of an FDA-approved drug that is not on the market. This is not the same as being an FDA-approved drug.
Unscheduled
No specific federal action; unaddressed at this time.

In limbo 17 compounds

Moved on paper - nominated, removed from a restricted list, or recommended by an FDA committee - but not added to the 503A list. The headline implies a change; the legal status has not moved.

AOD-9604

AOD9604, LAT-8881, AOD-9604 acetate

  • US
  • AU
  • UK
  • EU
  • CA
  • Sport

Withdrawn from Category 2 in Sep 2024; PCAC voted 0-12 against the 503A list; not compoundable

Changed Sep 27, 2024 8 primary sources

BPC-157

Body Protection Compound 157, Bepecin, PL 14736

  • US
  • AU
  • UK
  • EU
  • CA
  • Sport

PCAC recommended listing (8-6, Jul 23, 2026) - advisory only; still not on the 503A list

Changed Aug 25, 2026 10 primary sources

CJC-1295

Modified GRF 1-29, DAC:GRF, CJC-1295 DAC

  • US
  • AU
  • UK
  • EU
  • CA
  • Sport

PCAC voted against listing (Dec 2024); off Category 2, not on the 503A list

Changed Dec 4, 2024 4 primary sources

Dihexa

Dihexa acetate, PNB-0408, ATH-1001

  • US
  • AU
  • UK
  • EU
  • CA
  • Sport

Removed from Category 2 Apr 22, 2026, not on the 503A list; PCAC review expected before end of Feb 2027

Next Feb 28, 2027Changed Apr 22, 2026 9 primary sources

Emideltide (DSIP)

Delta sleep-inducing peptide, DSIP, Emideltide acetate

  • US
  • AU
  • UK
  • EU
  • CA
  • Sport

PCAC voted against listing (6-7, Jul 24, 2026); not on the 503A list

Changed Jul 24, 2026 8 primary sources

Epitalon

Epithalon, Epithalone, AEDG

  • US
  • AU
  • UK
  • EU
  • CA
  • Sport

PCAC recommended listing (reported 7-4, Jul 24, 2026) - advisory only; still not on the 503A list

Changed Jul 24, 2026 8 primary sources

GHK-Cu

Copper tripeptide-1, Copper peptide, GHK-copper

  • US
  • AU
  • UK
  • EU
  • CA
  • Sport

Injectable removed from Category 2, not on the 503A list; PCAC review expected before end of Feb 2027

Next Feb 28, 2027Changed Apr 22, 2026 5 primary sources

Ipamorelin

Ipamorelin acetate

  • US
  • AU
  • UK
  • EU
  • CA
  • Sport

PCAC voted against listing (Oct 2024); off Category 2, not on the 503A list

Changed Oct 29, 2024 5 primary sources

KPV

Lysine-proline-valine, Lys-Pro-Val, KPV acetate

  • US
  • AU
  • UK
  • EU
  • CA
  • Sport

PCAC recommended listing (8-6, Jul 23, 2026) - advisory only; still not on the 503A list

Changed Jul 23, 2026 7 primary sources

LL-37 (cathelicidin)

Cathelicidin LL-37, Ropocamptide

  • US
  • AU
  • UK
  • EU
  • CA
  • Sport

Removed from Category 2 Apr 22, 2026, not on the 503A list; PCAC review expected before end of Feb 2027

Next Feb 28, 2027Changed Apr 22, 2026 9 primary sources

Melanotan II

MT-II, MT-2, Melanotan-2

  • US
  • AU
  • UK
  • EU
  • CA
  • Sport

Off Category 2, not on the 503A list; PCAC review expected before end of Feb 2027

Next Feb 28, 2027Changed Apr 22, 2026 5 primary sources

MOTS-c

MOTs-C, Mitochondrial-derived peptide, MOTS-c acetate

  • US
  • AU
  • UK
  • EU
  • CA
  • Sport

PCAC recommended listing (7-5, Jul 23, 2026) - advisory only; still not on the 503A list

Changed Aug 25, 2026 12 primary sources

NAD+

Nicotinamide adenine dinucleotide, NAD, β-NAD

  • US
  • AU
  • UK
  • EU
  • CA
  • Sport

Not on the finalized 503A list; no federal ban; compounded in a gray area

Changed Sep 5, 2019 4 primary sources

Selank

Selank acetate, TP-7

  • US
  • AU
  • UK
  • EU
  • CA
  • Sport

Removed from Category 2 (2024); not on the 503A list; no scheduled review

Changed Sep 27, 2024 4 primary sources

Semax

Semax acetate

  • US
  • AU
  • UK
  • EU
  • CA
  • Sport

PCAC recommended listing (8-5, Jul 24, 2026) - advisory only; still not on the 503A list

Changed Aug 25, 2026 8 primary sources

TB-500 (Thymosin Beta-4)

TB-500, Thymosin Beta-4, TB-4

  • US
  • AU
  • UK
  • EU
  • CA
  • Sport

PCAC recommended listing (8-6, Jul 23, 2026) - advisory only; still not on the 503A list

Changed Aug 25, 2026 10 primary sources

Thymosin Alpha-1

Thymalfasin, Zadaxin, Tα1

  • US
  • AU
  • UK
  • EU
  • CA
  • Sport

Off Category 2, never in Category 1; PCAC declined Dec 2024

Changed Dec 4, 2024 6 primary sources

Restricted 8 compounds

Prescription-only, banned, controlled, or under active FDA enforcement.

Cagrilintide

AM833, long-acting amylin analog, CagriSema (combination with semaglutide)

  • US
  • AU
  • UK
  • EU
  • CA
  • Sport

Investigational only - no approved form exists anywhere; cannot be compounded; the CagriSema combination is under FDA review

Next Dec 31, 2026Changed Dec 18, 2025 7 primary sources

Kisspeptin-10

Metastin 45-54, Kisspeptin 112-121, KP10

  • US
  • AU
  • UK
  • EU
  • CA
  • Sport

FDA 503A Category 2 (significant safety risks) since Sep 29, 2023; advisory committee voted 0-11 against listing

Changed Sep 29, 2023 10 primary sources

PT-141 (bremelanotide)

Bremelanotide, Vyleesi, Bremelanotide acetate

  • US
  • AU
  • UK
  • EU
  • CA
  • Sport

FDA-approved prescription drug (Vyleesi, 2019); pharmacies may not routinely compound copies of it

Changed Jun 21, 2019 10 primary sources

Retatrutide

LY3437943, GIP/GLP-1/glucagon triple agonist, triple G

  • US
  • AU
  • UK
  • EU
  • CA
  • Sport

Investigational only - no approved form exists anywhere; cannot be compounded; FDA warning letters target sellers

Next Mar 31, 2027Changed Sep 9, 2025 8 primary sources

Semaglutide (compounded)

Ozempic, Wegovy, compounded semaglutide

  • US
  • AU
  • UK
  • EU
  • CA
  • Sport

Enforcement discretion ended; routine compounding no longer permitted. 503B exclusion proposed - comments closed Jul 30, 2026, decision pending

Changed Sep 18, 2026 10 primary sources

SS-31 (elamipretide)

Elamipretide, Elamipretide hydrochloride, Forzinity

  • US
  • AU
  • UK
  • EU
  • CA
  • Sport

FDA-approved prescription drug (Forzinity, Sep 2025); copies cannot be compounded and the acetate salt is ineligible

Changed Sep 19, 2025 10 primary sources

Tesamorelin

Egrifta, Egrifta SV, Egrifta WR

  • US
  • AU
  • UK
  • EU
  • CA
  • Sport

Licensed biologic (Egrifta SV, Egrifta WR) since Mar 23, 2020 - outside the 503A and 503B compounding exemptions

Changed Mar 23, 2020 10 primary sources

Tirzepatide (compounded)

Mounjaro, Zepbound, compounded tirzepatide

  • US
  • AU
  • UK
  • EU
  • CA
  • Sport

Enforcement discretion ended; broad compounding no longer permitted. 503B exclusion proposed - comments closed Jul 30, 2026, decision pending

Changed Sep 18, 2026 6 primary sources

Compounding-legal 1 compound

A licensed pharmacy may compound it on prescription: it is on the FDA 503A bulk-substances list or is an ingredient of an FDA-approved drug that is not on the market. This is not the same as being an FDA-approved drug.

Sermorelin

GRF 1-29, Geref, Sermorelin acetate

  • US
  • AU
  • UK
  • EU
  • CA
  • Sport

Not on any 503A list; compounded as a component of Geref, an FDA-approved drug withdrawn in 2009 for non-safety reasons

Changed Mar 4, 2013 9 primary sources

Outside the U.S.

Everywhere else, the answer is simpler

13 of 26 are restricted in every one of Australia, the UK, the EU and Canada, and In limbo exists only in the United States. See all 156 statuses side by side - free to download and reuse.

See the gridCSVJSON

Who runs this - and why it stays neutral

Peptlas is maintained by the Peptlas Research Team, an independent group. We sell nothing - no products, no affiliates, no sponsors - so we have no stake in what any status turns out to be. Every entry links to its primary source and carries a human-verified date, and every change is logged in the open.

About usHow we track itThe public record

Informational only - not medical or legal advice, and no health claim. Always confirm against the linked primary source. Full disclaimer.